Clinical trial

S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With…

NCT00066794 · SWOG Cancer Research Network, Other · Completed

Key facts

NCT number NCT00066794
Title S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Official title A Phase II Study Of Induction With Daunorubicin, Cytarabine, And Cyclosporine All By Continuous IV Infusion For Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) In Patients Of Age 56 Or Older
Lead sponsor SWOG Cancer Research Network, Other
Collaborators National Cancer Institute (NCI) NIH
Status Completed
Phase Phase 2
Study type Interventional
Conditions Leukemia
Intervention type Biological, Drug
Interventions filgrastim, sargramostim, cyclosporine, cytarabine, daunorubicin hydrochloride
Enrollment 69
Start date Jul 1, 2004
Primary completion Feb 1, 2007
Completion Jan 1, 2010
First posted Aug 7, 2003
Last update posted Mar 6, 2015
Countries United States

At a glance

  • 10–99 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies